2019-SMR-GSK-3β blockade with 9-ING-41 in melanoma: The 1801 Phase 1/2 study
2019-SMR-GSK-3β blockade with 9-ING-41 in melanoma: The 1801 Phase 1/2 study Read More »
Search Results for: -iujaa.html
ACTUATE THERAPEUTICS COMPLETES $6.5 MILLION SERIES B-3 FINANCING TO EXPAND CLINICAL PROGRAMS
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised an additional $6.5M in a Series B-3 financing round. This Series B-3 was led by Bios Partners with Kairos Ventures, DEFTA Partners, and other existing investors participating, and brings total funding for Actuate’s Series B
ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B financing round. The Series B is led by Kairos Ventures, with DEFTA Partners, Tech Coast Angels, and existing investors, Bios Partners, participating. Actuate will use the proceeds of the
ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING Read More »
ACTUATE THERAPEUTICS OPENS PHASE 1 / 2 CLINICAL STUDY OF 9-ING-41 IN PATIENTS WITH REFRACTORY CANCERS
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in patients with refractory hematologic malignancies or solid tumors. “Opening enrollment on our first